lu 135252 has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kirchengast, M; Lemmer, B; Reitenbach, I; Schilling, L; Stolpe, K; Witte, K | 1 |
| Amann, K; Gross, ML; Helmke, B; Münter, K; Parkman, A; Ritz, E; Schoof, A; Tulp, O | 1 |
2 other study(ies) available for lu 135252 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of the endothelin a receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats.
Topics: Acetylcholine; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Endothelin A Receptor Antagonists; Endothelium, Vascular; Guanylate Cyclase; Heart Rate; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Muscle Contraction; Muscle, Smooth, Vascular; Nitroprusside; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Time Factors; Vasodilator Agents | 2003 |
Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Immunohistochemistry; Indoles; Kidney; Male; Phenylpropionates; Proliferating Cell Nuclear Antigen; Pyrimidines; Rats; RNA, Messenger; Transforming Growth Factor beta | 2003 |